Literature DB >> 30118994

Association between dysfunction of autonomic nervous system activity and mortality in schizophrenia.

Saki Hattori1, Akira Suda2, Ikuko Kishida3, Masatoshi Miyauchi2, Yohko Shiraishi2, Mami Fujibayashi4, Natsuki Tsujita5, Chie Ishii6, Norio Ishii6, Toshio Moritani7, Yusuke Saigusa8, Yoshio Hirayasu9.   

Abstract

BACKGROUND: Patients with schizophrenia have a higher mortality risk than the general population. Additionally, the autonomic nervous system (ANS) activity of patients with schizophrenia is lower and more dysfunctional than that of the general population. Nonetheless, the association between ANS dysfunction and mortality in schizophrenia is unclear. The aim of this study was to investigate the association between ANS activity and mortality in schizophrenia and to evaluate the predictive values of heart rate variability for long-term survival.
METHODS: This study involves the 10-year follow-up of a sample population consisting of 59 Japanese inpatients with schizophrenia between 60 and 70 years of age from 2007 to 2016. The ANS activity of all patients was evaluated using heart rate variability in 2007.
RESULTS: Fifty-three participants could be followed up because they stayed in the hospital during the follow-up period. Of these patients, 11 died during follow-up. Their mean age at death was 70.55 ± 3.45 years. The parasympathetic activity of nonsurvivors was significantly lower than that of survivors, and multiple logistic regression analysis showed a significant association between death and parasympathetic activity.
CONCLUSION: We suggest that decreased parasympathetic activity could be associated with 10-year all-cause mortality in older schizophrenic patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30118994     DOI: 10.1016/j.comppsych.2018.08.002

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  2 in total

1.  Salivary Flow Alteration in Patients Undergoing Treatment for Schizophrenia: Disease-Drug-Target Gene/Protein Association Study for Side-effects.

Authors:  Anusa Arunachalam Mohandoss; Rooban Thavarajah
Journal:  J Oral Biol Craniofac Res       Date:  2019-06-15

Review 2.  Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health.

Authors:  Margaret K Hahn; Sri Mahavir Agarwal; Nicolette Stogios; Alexander Gdanski; Philip Gerretsen; Araba F Chintoh; Ariel Graff-Guerrero; Tarek K Rajji; Gary Remington
Journal:  NPJ Schizophr       Date:  2021-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.